Body Vision Medical said today it won FDA clearance for its LungVision lung navigation catheter.
The Israel-based company said its LungVision catheter is designed for use in conjunction with standard bronchoscopes and its LungVision system for guiding endotherapy accessories to small pulmonary modules.
“Body Vision has pioneered a new generation platform for navigation bronchoscopy that applies augmented reality approach to plan, visualize, and accurately track radiolucent bronchial nodules in real time. LungVision navigation tool has clear performance and cost benefits over current navigation tools that are bound to electro-magnetic sensing,” Dr. Krish Bhadra of CHI Memorial Hospital said in a prepared statement.
Body Vision Medical said the clearance will allow it to accelerate commercialization efforts for the LungVision platform as a whole. The LungVision imaging and navigation system was cleared last May, the company said.
“We are thrilled to introduce the LungVision tool to the medical community and patients. This FDA clearance paves the way for the LungVision platform to become the preferred choice in bronchoscopy for any lung cancer center in the U.S. We envision, this affordable LungVision platform will revolutionize the way physicians diagnose and treat peripheral lung lesions,” Body Vision CEO Dorian Averbuch said in a press release.
